QIAGEN N.V.
QIAGEN N.V. (QGEN): 10 pipeline candidates · 10 upcoming catalysts · ~5 mo cash runway · 2 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
4.9 months
N/A
Lead: Approved
10 candidates
10 upcoming, next in ~36d
N/A
A transparent, data-derived signal for QIAGEN N.V.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$7.5B
Cash
$839.0M
Quarterly Burn
$833.6M
Runway
4.9 mo
Revenue
$2.1B
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (10 candidates)
| Drug | Phase |
|---|---|
| artus cmv rgq | Approved |
| butalbital | Approved |
| ipsogen jak2 rgq pcr kit | — |
| lidocaine | Approved |
| oxycodone | Approved |
| partosure test | Approved |
| quantiferon-tb gold | — |
| therascreen egfr rgq pcr kit | — |
| triamcinolone acetonide | Approved |
| virapap human papillomavirus dna detection kit | — |
Upcoming Catalysts (10)
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
343
Total value held
$4.78B
| Holder | Shares | Value |
|---|---|---|
| wellington management group llp | 14,364,303 | $575.1M |
| vanguard capital management llc | 12,212,550 | $494.7M |
| deutsche bank ag\ | 5,601,957 | $224.3M |
| blackrock, inc. | 5,250,461 | $210.2M |
| morgan stanley | 4,190,913 | $167.8M |
| earnest partners llc | 3,868,489 | $154.9M |
| bank of america corp /de/ | 3,246,973 | $130.0M |
| fivespan partners, lp | 2,689,243 | $107.7M |
| allspring global investments holdings, llc | 2,481,645 | $100.2M |
| capital international investors | 2,436,169 | $97.5M |
Showing top 10 of 343 institutional holders of QIAGEN N.V.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in QIAGEN N.V.'s pipeline?
QIAGEN N.V. (QGEN) has 10 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is QIAGEN N.V.'s lead drug candidate?
QIAGEN N.V.'s most advanced tracked candidate is artus cmv rgq (Approved) for Microbiology.
What is QIAGEN N.V.'s next catalyst?
QIAGEN N.V.'s next tracked catalyst is a Patent_Expiry event — "Patent/Exclusivity Expiry: AKTEN" — expected July 24, 2026.
What is QIAGEN N.V.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, QIAGEN N.V. has approximately 4.9 months of cash runway.
What is QIAGEN N.V.'s market capitalization?
QIAGEN N.V.'s market capitalization is approximately $7.5B.
Get the full picture on QIAGEN N.V.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.